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Abstract (247 words) 1 
 2 
Aims/hypothesis: There has been long-standing debate whether diabetes is a causal risk factor 3 
for pancreatic cancer or a consequence of tumour development. Prospective epidemiologic 4 
studies have shown variable relationships of pancreatic cancer risk with blood markers of 5 
glucose and insulin metabolism, overall and as a function of lag-times between marker 6 
measurements (blood donation) and date of tumour diagnosis. 7 
Methods: Pre-diagnostic levels of HbA1c and C-peptide were measured for 466 pancreatic 8 
cancer cases and 466 individually matched controls within the European Prospective 9 
Investigation into Cancer and Nutrition. Conditional logistic regression models were used to 10 
estimate ORs for pancreatic cancer. 11 
Results: Pancreatic cancer risk gradually increased with increasing pre-diagnostic HbA1c 12 
levels up to an OR of 2.42 (95% CI 1.33, 4.39 highest (≥ 6.5%, 48 mmol/mol) vs. lowest (≤ 13 
5.4%, 36 mmol/mol) category), even for subjects with HbA1c levels within the non-diabetic 14 
range. C-peptide levels showed no significant relationship with pancreatic cancer risk, 15 
irrespective of fasting status. Analyses showed no clear trends towards increasing 16 
hyperglycaemia (as marked by HbA1c levels) or reduced pancreatic beta cell responsiveness 17 
(as marked by C-peptide levels) with reducing time intervals from blood donation till cancer 18 
diagnosis. 19 
Conclusions/interpretation: Our data on HbA1c show that subjects who develop exocrine 20 
pancreatic cancer tend to have moderate increases in HbA1c levels, relatively independently 21 
of obesity and insulin resistance – the classical and major risk factors for type 2 diabetes. 22 
While there is no strong difference by lag time, more data is needed on this to come to a firm 23 
conclusion. 24 
 25 
Key words: HbA1c, C-peptide, pancreatic cancer, diabetes, EPIC, cohort study 26 
 27 
Abbreviations: 28 
EPIC: European Prospective Investigation into Cancer and Nutrition 29 
30 
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Introduction 1 
 2 
Well-established lifestyle and environmental risk factors for exocrine pancreatic cancer 3 
include smoking [1, 2], chronic and acute forms of pancreatitis [3], and excess body weight 4 
[4], although the latter is a rather weak risk factor for pancreatic cancer in comparison to 5 
several other cancer types [5]. 6 
A further, well-documented risk factor for pancreatic cancer is long-standing diabetes, 7 
although many studies have also documented the occurrence of diabetes relatively shortly 8 
prior to diagnosis of a pancreatic tumour. This adds fuel to the debate as to whether diabetes 9 
is a possible cause, or more likely a consequence of tumour development [6, 7]. In relation to 10 
the first theory, it has been speculated that elevated plasma glucose levels and/or increased 11 
pancreatic insulin secretion, which are both intrinsic to the development of type 2 diabetes, 12 
could serve as possible mechanisms explaining the risk association between diabetes and 13 
pancreatic tumour development, e.g. by stimulating cellular growth and by inhibiting 14 
apoptosis [8, 9]. According to the second theory, diabetes would occur primarily as a result of 15 
a developing tumour, which progressively may entrap or invade pancreatic beta cell islets 16 
[10], thus causing a gradual destruction of functional beta cell capacity [11], reductions in 17 
insulin secretion capacity, and progressive hyperglycaemia. 18 
To further elucidate the possible cause and/or effect relationships between diabetes 19 
mellitus and pancreatic cancer, it is important to further elucidate the temporal relationship 20 
between pancreatic cancer occurrence and pre-existing disturbances of glucose and insulin 21 
metabolism. Previous prospective studies have shown statistically significant associations of 22 
pre-diagnostic glucose [12-15] and insulin levels [15, 16] with pancreatic cancer risk, 23 
however, results were inconsistent when lag-time was taken into consideration. 24 
Here, we report results from a nested case-control study within the European 25 
Prospective Investigation into Cancer and Nutrition (EPIC), measuring pre-diagnostic serum 26 
levels of HbA1c and C-peptide in healthy subjects at enrolment, to calculate risk estimates for 27 
the association of those markers with pancreatic cancer. To examine the complex, possibly 28 
time-dependent relationship of glucose, insulin, diabetes and pancreatic cancer, we 29 
additionally stratified our analyses by lag-time between study enrolment (with blood 30 
donation) and pancreatic cancer diagnosis. 31 
 32 
 33 
Research Design and Methods 34 
 35 
Study Population 36 
The design and methods of the EPIC study have been described previously [17, 18]. 37 
Briefly, 519,978 men and women, mostly aged between 35 and 70 years, were recruited by 23 38 
collaborating centres in 10 European countries (Denmark, France, Germany, Greece, Italy, the 39 
Netherlands, Norway, Spain, Sweden, and the United Kingdom) between 1992 and 2000. 40 
Ethical review boards of IARC and local institutions gave approval for the study and all 41 
participants provided informed consent. 42 
 43 
Blood Sample Collection and Storage 44 
In seven EPIC countries (France, Germany, Greece, Italy, the Netherlands, Spain, and 45 
the United Kingdom) serum, plasma, erythrocytes, and DNA was aliquoted and stored in 46 
liquid nitrogen (-196°C) in a central biorepository. In Denmark blood samples were stored 47 
locally in nitrogen vapour (-150°C) and in Sweden in freezers at -70°C. For the present study, 48 
Norway was excluded because blood samples had only recently been collected and very few 49 
pancreatic cancer cases had been diagnosed after blood donation. 50 
 51 
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Follow-up for Cancer Incidence and Vital Status 1 
Incident cancer cases were identified by population cancer registries (Denmark, Italy, 2 
the Netherlands, Spain, Sweden, and the United Kingdom) or by a combination of methods 3 
including health insurance records, cancer and pathology registries, and active follow-up 4 
through study subjects (France, Germany, Greece). In all EPIC centres, data on vital status are 5 
collected through mortality registries, in combination with health insurance data (France) or 6 
active follow-up (Greece). For the present project on pancreatic cancer, the study period was 7 
defined as the latest dates of complete follow-up for both cancer incidence and vital status in 8 
each EPIC centre; varying from December 2002 to December 2006. For Germany, Greece, 9 
and France, the end of follow-up was considered to be the last known contact, the date of 10 
diagnosis, or the date of death, whichever came first. 11 
 12 
Selection of Case and Control Subjects 13 
Pancreatic cancer incidence data were coded according to ICD-10 and included all 14 
invasive exocrine pancreatic cancers that were coded as C25 (25.0-25.3, 25.7-25.9). Exclusion 15 
criteria were occurrence of other malignant tumours preceding the diagnosis of pancreatic 16 
cancer, except for non-melanoma skin cancer, and non-availability of blood specimens. By 17 
the end of December 2006, 638 incident cases of pancreatic cancer were identified, of which 18 
578 were primary exocrine pancreatic tumours. For 466 of these cases blood specimens were 19 
available. Of these, 342 (76%) were microscopically confirmed. For the remaining 24% 20 
diagnosis was confirmed by clinical symptoms, imaging results, and/or physical examination. 21 
For each case, one control subject, alive and free of cancer at time of diagnosis of the index 22 
case, was selected using incidence density sampling. Matching characteristics were study 23 
centre sex, age at enrolment (± 6 months), date at entry in the cohort, time between blood 24 
sampling and time of last consumption of foods and drinks (< 3 hours, 3-6 hours, ≥ 6 hours). 25 
 26 
Laboratory Assays 27 
Serum or EDTA plasma samples (Swedish centres) from cases and individually 28 
matched controls from one centre were analyzed within the same analytical batch. HbA1c was 29 
measured in erythrocyte hemolysate with the BioRad Variant Haemoglobin Analyzer at the 30 
Karolinska University Laboratory (Karolinska University Hospital, Stockholm, Sweden). 31 
Units are expressed as percentages of haemoglobin and in mmol/mol. C-peptide was analyzed 32 
by double antibody radioimmunoassay using the RIA DSL-7000 kit (Diagnostic Systems 33 
Laboratories Inc., Webster, Texas, USA) at the German Cancer Research Centre, Division of 34 
Cancer Epidemiology (Heidelberg, Germany). Units of C-peptide are expressed as ng/ml. 35 
Mean intra-batch and inter-batch coefficients of variations were 2.5 % and 4.4 % for HbA1c, 36 
and 8.3% and 19% for C-Peptide. 37 
 38 
Statistical Analyses 39 
Differences between cases and controls were tested by paired t-tests for continuous 40 
variables and by χ2 tests for categorical variables. 41 
Conditional logistic regression was used to calculate odds ratios (OR) and the 42 
corresponding 95% confidence intervals (CI) for the associations between HbA1c and C-43 
peptide and pancreatic cancer risk; HbA1c and C-peptide were computed on a continuous 44 
scale and as categorized variables. Continuous measurements of C-peptide were log-45 
transformed to approximate normality, whereas transformation of HbA1c levels had no effect 46 
on normality and odds ratios, therefore non-transformed HbA1c values were used in all 47 
statistical procedures. Category cut-points were based on the distribution among controls and 48 
p-values for trends across categories were based on the median values within each quartile. To 49 
assess the association of pancreatic cancer risk among individuals at the highest risk for 50 
progression to diabetes (HbA1c ≥ 6.0 (42 mmol/mol) and < 6.5% (48 mmol/mol)) and among 51 
4 
 
those having diabetes (HbA1c ≥ 6.5% (48 mmol/mol)) [19], the highest HbA1c category was 1 
further divided into these two groups. ORs were also computed to assess the association of 2 
diabetes with pancreatic cancer risk. In general, subjects were defined as diabetics if they self-3 
reported the condition at recruitment and/or had HbA1c levels ≥ 6.5% (48 mmol/mol) at 4 
baseline (n=95). 5 
Conditional logistic regression was also used to assess the association of possible 6 
confounders with pancreatic cancer risk other than those controlled for by matching; these 7 
include BMI (continuous), waist circumference (continuous), WHR (continuous), alcohol 8 
intake at recruitment (continuous), physical activity (active, moderately active, moderately 9 
inactive, inactive), smoking status (never, former, current, missing), and diabetes at 10 
recruitment (yes, no, missing). Variables remained in the model if they were associated with 11 
pancreatic cancer, correlated with HbA1c or C-peptide, or changed the logistic β estimate by 12 
more than 10%. We finally adjusted for BMI as a continuous variable and for smoking status 13 
as a categorical variable (never smoker; former smoker who stopped less than 10 years ago, 14 
former smokers who stopped 10 or more years ago; current smokers with 1-9, 10-19, or ≥ 20 15 
cigarettes per day; smoking status unknown). To explore further possible confounding effects, 16 
we additionally adjusted for C-peptide or HbA1c in further models. 17 
In addition, analyses were stratified by factors that could modify the relationship 18 
between HbA1c or C-peptide levels and pancreatic cancer. Tests for statistical heterogeneity 19 
between subgroups were calculated by adding cross-product terms in the logistic regression 20 
models over quartiles of HbA1c and C-peptide and testing the significance with the Wald test, 21 
adjusted for confounders. 22 
All statistical analyses were conducted using the Statistical Analysis System (SAS) 23 
software package, Version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). 24 
 25 
 26 
Results 27 
 28 
Baseline characteristics of the study population are shown in Table 1. Mean follow-up 29 
time for cases was 5.3 years (range 0-13 years). Thirty two percent of cases were current 30 
smokers compared to 22% of controls, whereas never smokers were more common among 31 
controls than among cases. At baseline recruitment, diabetes, either self-reported or defined 32 
by elevated HbA1c levels, was more frequent among those who developed pancreatic cancer. 33 
Among women, incident pancreatic cancer cases had a significantly higher BMI and 34 
waist circumference than their matched controls but no significant differences in BMI or waist 35 
circumference were seen among men (Table 1). Stratifying by smoking and diabetes status, 36 
significant case-control differences in BMI and waist circumference appeared to be restricted 37 
to never smoking diabetics. Case-control differences in HbA1c were greatest among former 38 
smokers, and particularly among former smokers who were also diabetic at baseline (meancases 39 
= 8.1% (65 mmol/mol), meancontrols = 6.6% (49 mmol/mol), p-difference = 0.002). C-peptide 40 
concentrations were significantly higher among non-fasting (geometric mean = 6.59 [95% CI 41 
6.10, 7.13]) compared to fasting subjects (3.35 [3.04, 3.70]), and among diabetics (6.83 [5.64, 42 
8.27]) compared to non-diabetics (5.07 [4.79, 5.36]). In addition, former smokers (6.24 [5.74, 43 
6.78]) had higher C-peptide levels than current (5.13 [4.62, 5.69]) and never smokers (4.59 44 
[4.21, 5.02]). 45 
 46 
 47 
Association of diabetes with cancer risk: 48 
Conditional logistic regression analyses showed a clear increase in pancreatic cancer 49 
risk overall among diabetic subjects at recruitment (OR = 1.74 [95% CI 1.12-2.71]). This 50 
association was particularly strong among subjects with a follow-up time of two years or less 51 
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(OR=3.41 [95% CI 1.26-9.20]), as compared to those with a longer follow-up time (OR=1.45 1 
[95% CI 0.89-2.37]), although heterogeneity was not significant (p = 0.227). 2 
 3 
Associations of HbA1c with cancer risk: 4 
Increasing HbA1c percentages were associated with a statistically significant increase in 5 
pancreatic cancer risk up to an OR of 2.60 comparing highest vs. lowest category (Table 2). 6 
Multivariate adjustment for BMI, or waist circumference, and smoking status as well as C-7 
peptide levels only slightly attenuated this risk association. 8 
Analyses by lag-time between the date of blood donation (biomarker measurements) 9 
and date of pancreatic cancer diagnosis showed no statistically significant heterogeneity of the 10 
association of HbA1c with pancreatic cancer risk, although the association was somewhat 11 
stronger for subjects with follow-up times above the median length of follow-up of 5.2 years 12 
than for those with shorter follow-up times (Table 2). Also, within less than two years of 13 
follow-up the association between HbA1c concentrations and pancreatic cancer risk was of 14 
similar strength (adjusted OR = 1.39 [95% CI 0.48, 4.03]) to that seen for longer follow-up 15 
times (adjusted OR = 1.57 [95% CI 0.97, 2.54]; p-heterogeneity = 0.038). 16 
Although trend tests over categories of HbA1c did not show a statistically significant 17 
heterogeneity by smoking status, stratification by smoking status did reveal a clearly stronger 18 
increase in pancreatic cancer risk with increasing HbA1c concentrations for never smokers, a 19 
somewhat weaker increase in risk among ex-smokers, and no increase in risk with increasing 20 
HbA1c among current smokers (Table 2). 21 
 22 
Associations of C-peptide with cancer risk: 23 
Overall, C-peptide concentrations showed no significant relationship with pancreatic 24 
cancer risk (Table 3). Multivariate adjustments for BMI or waist circumference, smoking 25 
categories, or HbA1c, or exclusion of diabetic subjects did not materially change these odds 26 
ratio estimates. However, among subjects who had provided a blood sample under fasting 27 
conditions (last food consumption ≥ 6 hours ago), increasing C-peptide levels did show a 28 
tendency of increasing risks of pancreatic cancer, although risk was not statistically 29 
significant (Table 3). 30 
Odds ratio estimates for increasing C-peptide levels did not vary by length of follow-up 31 
or smoking status (data not shown). 32 
 33 
Further analyses stratified by sex, diabetes status, median BMI or waist circumference 34 
did not show statistically significant heterogeneity between these strata for risk associations 35 
with HbA1c or C-peptide (data not shown). 36 
 37 
Discussion 38 
 39 
In this prospective study, we observed an increase in pancreatic cancer risk with 40 
increasing pre-diagnostic HbA1c levels, even for subjects with HbA1c levels within the non-41 
diabetic range. The association was only slightly weakened and remained statistically 42 
significant after adjustments for BMI or smoking status, and in stratified analyses was most 43 
apparent among never smokers. Contrary to HbA1c, pre-diagnostic levels of C-peptide 44 
showed no significant associations with pancreatic cancer risk, irrespective of smoking or 45 
fasting status. Lag-time analyses showed no clear difference in the association of pancreatic 46 
cancer risk with HbA1c or C-peptide levels by longer or shorter follow-up times. 47 
 48 
With respect to HbA1c – a relatively stable and long-term marker for blood glucose 49 
levels [19] – our data showed evidence of an association of elevated HbA1c concentrations 50 
with increased pancreatic cancer risk independently of diabetes. Indeed, the increase in 51 
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pancreatic cancer risk was statistically significant as from the third category of HbA1c (5.8-1 
5.9% (40-41 mmol/mol)), which does not include diabetic subjects (≥ 6.5% (48 mmol/mol)) 2 
or even individuals at the highest risk for progression to diabetes (≥ 6.0% (42 mmol/mol) and 3 
< 6.5% (48 mmol/mol)) based on the definitions of the American Diabetes Association [19]. 4 
With few exceptions [20], previous prospective studies have shown statistically significant 5 
associations of pre-diagnostic glucose levels with pancreatic cancer risk [12-15], and in these 6 
studies, a clear increase in risk was also visible among subjects with intermediate, non-7 
diabetic levels of glycaemia. 8 
Our findings for C-peptide – no significant association with pancreatic cancer risk 9 
overall, under fasting or non-fasting conditions – contrast with those from other studies. In a 10 
study of four pooled prospective cohorts in the USA, Michaud et al. did observe an increase 11 
in pancreatic cancer risk for the highest quartile level of non-fasting plasma C-peptide, but no 12 
association with fasting C-peptide [16]. In the Finnish ATBC cohort, by contrast, pancreatic 13 
cancer risk was significantly elevated for the highest quartile of fasting serum insulin [15]. 14 
 15 
Obesity is an important and frequent determinant of insulin resistance and chronic 16 
hyperinsulinemia [21], and a very strong risk factor for type 2 diabetes [22]. Paradoxically, 17 
however, epidemiologic studies have globally shown only very modest associations of 18 
pancreatic cancer risk with BMI or other anthropometric measures of adiposity [4]. Our data 19 
showed clear positive correlations of BMI or waist circumference with C-peptide, but very 20 
little correlation of these adiposity indices with HbA1c (data not shown), in line with findings 21 
from other studies [23, 24]. 22 
Adiposity-related insulin resistance, while leading to increased plasma insulin levels, 23 
may generally not be the only, or even principal cause for increases in blood glucose levels. 24 
Indeed, hyperglycaemia is generally related to a degree of pancreatic beta cell deficiency and 25 
insufficient insulin secretion in response to rising glucose levels, and such deficiency is also a 26 
central hallmark of all major forms of diabetes. The molecular-pathologic pathways leading to 27 
the deficiency vary between different forms of diabetes, and it is conceivable that relatively 28 
specific forms of pancreatic pathology are at the origin of the hyperglycaemia in subjects who 29 
subsequently develop pancreatic cancer. Based on observations indicating that inflammatory 30 
pathways play a very central role in the development of pancreatic cancer [25, 26] while 31 
potentially contributing also to the development of diabetes [27], we speculate that such 32 
specific pathology could be a form of chronic and low-grade pancreatic inflammation. 33 
 34 
Under the hypothesis that, indeed, a chronic and low-grade form of pancreatic 35 
pathology is an original cause of hyperglycaemia in subjects who later develop pancreatic 36 
malignancies, we examined whether there are signs of moderate and progressive impairment 37 
of the pancreatic beta cell responsiveness, as time intervals till diagnosis of a pancreatic 38 
tumour get shorter. Our analyses, however, showed only little heterogeneity of the 39 
associations of C-peptide and HbA1c levels with pancreatic cancer risk by length of lag-time 40 
till cancer diagnosis. Similar lag-time analyses in other prospective studies have led to 41 
inconsistent findings so far. In the pooled US cohort [16] and the ATBC cohort [15], there 42 
were indications for a stronger association of C-peptide and fasting insulin and glucose levels, 43 
respectively, with longer follow-up, whereas two other prospective cohort studies on blood 44 
glucose levels and pancreatic cancer risk showed no heterogeneity of these associations by 45 
lag-time [12, 13]. 46 
 47 
A major strength of our nested case-control study is its prospective design, reducing to a 48 
certain extent the possibility of reverse causation, whereas a limitation is the single 49 
assessment of biochemical indicators, which may be susceptible to biological variation. 50 
 51 
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In conclusion, the results of our nested-case control study embedded in a large multi-1 
centre cohort support an association of increasing HbA1c levels with pancreatic cancer risk, 2 
independent of BMI or diabetes status. However, in contrast to some previous studies, we did 3 
not find an association of elevated C-peptide with pancreatic cancer risk. Overall, combining 4 
the results from prospective studies so far, data provide no coherent picture in terms of 5 
progressive alterations in glucose and/or insulin metabolism at greater or shorter time 6 
intervals prior to pancreatic cancer diagnosis. Further research is needed to understand 7 
whether elevated plasma glucose is a possible contributing cause for pancreatic cancer, or 8 
whether it is a mere epi-phenomenon pointing towards the existence of a moderate pancreatic 9 
disorder that predisposes to pancreatic cancer development as well as to diabetes. 10 
 11 
 12 
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Table 1: Baseline characteristics of pancreatic cancer cases and matched control subjects 
 
Variable Cases (n=466) Controls (n=466) P valuea 
Men, women (n) 225, 241 225, 241  
Age at recruitment (y), mean (range) 58 (30-76) 58 (30-76) matched 
Age at diagnosis (y), mean (range) 63 (37-82) -  
Follow-up (y), mean (range) 5.3 (0-13) -  
Smoking status, n (%)   0.005 
     Never 165 (35) 201 (43)  
     Former 147 (32) 158 (34)  
     Current 149 (32) 102 (22)  
     Unknown 5 (1) 5 (1)  
Alcohol intake at recruitment [g/d], mean ± SD    
     Men 21 ± 26 23 ± 30 0.486 
     Women 9 ± 13 8 ± 11 0.168 
Fasting status, n (%)   matched 
     Fasting (≥ 6 hours) 118 (25) 113 (24)  
     In between (3 - 6 hours) 78 (17) 78 (17)  
     Non fasting (< 3 hours) 184 (40) 190 (41)  
     Unknown 86 (18) 85 (18)  
Self-reported diabetes at recruitment, n (%) 33 (7) 20 (4) 0.065 
Subjects HbA1c ≥ 6.5%, n (%) 53 (12) 30 (7) 0.008 
Self-reported diabetes or HbA1c ≥ 6.5%, n (%) 59 (13) 36 (8) 0.012 
     Unknown, n (%) 19 (4) 18 (4)  
BMI [kg/m2], mean ± SD 26.6 ± 4.3 25.9 ± 4.1 0.007 
     Men 26.8 ± 3.6 26.7 ± 3.7 0.690 
     Women 26.4 ± 5.0 25.2 ± 4.3 0.002 
Waist circumference [cm], mean ± SD 90.1 ± 12.8 88.5 ± 13.1 0.030 
     Men 96.4 ± 9.9 96.7 ± 10.1 0.788 
     Women 84.2 ± 12.5 81.0 ± 10.7 0.001 
Waist-hip ratio, mean ± SD 0.88 ± 0.10 0.88 ± 0.10 0.110 
     Men 0.95 ± 0.06 0.95 ± 0.06 0.501 
     Women 0.81 ± 0.07 0.81 ± 0.06 0.119 
HbA1c [%], mean ± SD 6.01 ± 1.1 5.80 ± 0.6 < 0.0001 
C-peptide [ng/ml], geometric mean (95% CI)b 5.46 (5.08-5.86) 5.05 (4.67-5.47) 0.161 
 
n = number, y = year. HbA1c mean values in mmol/mol for cases = 42.2, for controls = 39.9 
a.
 P values for continuous variables were based on paired t-tests; p values for categorical variables were based 
on χ2 tests. 
b.
 C-peptide levels were reported as geometric means, as the distribution of the variable was not normal. 
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Table 2. Odds ratios (OR) for pancreatic cancer (95% CI) by categories of HbA1c overall and excluding diabetics; and stratified by median 
follow-up time, median BMI, and smoking status 
 
 Categoriesa  
 1 2 3 4 5 Ρ trendb 
Quartile cut-offs [%] 4.8- 5.4 5.5-5.7 5.8-5.9 6.0-6.4 6.5-11.0  
All subjectsc       
No. cases / controls 72 / 101 131 / 151 102 / 82 97 / 91 54 / 31  
Crude 1.0 1.24 (0.83-1.85) 1.75 (1.14-2.67) 1.59 (1.03-2.45) 2.60 (1.49-4.56) < 0.001 
Adjusted for smoking, BMI 1.0 1.27 (0.84-1.93) 1.77 (1.14-2.75) 1.46 (0.93-2.30) 2.42 (1.33-4.39) 0.002 
Excluding diabetic subjectsc,d       
No. cases / controls 65 / 89 122 / 134 95 / 71 83 / 71 -  
Crude 1.0 1.30 (0.85-1.98) 1.85 (1.18-2.91) 1.68 (1.05-2.70)  0.010 
Adjusted for smoking, BMI 1.0 1.42 (0.91-2.21) 1.94 (1.22-3.10) 1.65 (1.01-2.70)  0.020 
Median follow-up time (5.2yrs)c       
< 5.2 years, no. cases / controls 41 / 46 54 / 75 52 / 44 83 / 63 -  
Crude 1.0 0.89 (0.50-1.60) 1.44 (0.78-2.64) 1.65 (0.90-3.01)  0.069 
Adjusted for smoking, BMI 1.0 0.92 (0.50-1.69) 1.37 (0.73-2.56) 1.56 (0.82-2.94)  0.187 
≥ 5.2 years, no. cases / controls 33 / 55 77 / 77 51 / 38 68 / 59 -  
Crude 1.0 1.75 (1.00-3.04) 2.23 (1.22-4.07) 1.91 (1.09-3.35)  0.050 
Adjusted for smoking, BMI 1.0 1.73 (0.95-3.15) 2.39 (1.26-4.54) 1.74 (0.95-3.18)  0.061 
Median BMI (men 26.7, women 24.6)e       
< Median, no. cases / controls 40 / 57 65 / 79 48 / 38 51 / 53 -  
Crude 1.0 1.16 (0.68-1.96) 1.75 (0.96-3.19) 1.37 (0.77-2.45)  0.150 
Adjusted for smoking 1.0 1.16 (0.67-2.00) 1.41 (0.76-2.63) 1.22 (0.67-2.23)  0.442 
≥ Median, no. cases / controls 34 / 44 66 / 73 55 / 44 100 / 69 -  
Crude 1.0 1.25 (0.71-2.21) 1.73 (0.94-3.18) 2.07 (1.18-3.62)  0.004 
Adjusted for smoking 1.0 1.27 (0.72-2.27) 1.81 (0.98-3.36) 1.92 (1.08-3.41)  0.013 
Smoking statuse       
Never smoker, no. cases / controls 25 / 54 55 / 64 37 / 35 47 / 44 -  
Crude 1.0 1.84 (1.01-3.37) 2.36 (1.20-4.64) 2.41 (1.26-4.60)  0.008 
Adjusted for BMI 1.0 1.76 (0.96-3.23) 2.20 (1.11-4.34) 2.15 (1.11-4.17)  0.025 
Former smoker, no. cases / controls 19 / 30 42 / 54 32 / 25 50 / 45 -  
Crude 1.0 1.20 (0.58-2.49) 1.97 (0.88-4.42) 1.73 (0.83-3.60)  0.079 
Adjusted for BMI 1.0 1.19 (0.58-2.46) 1.93 (0.86-4.35) 1.65 (0.78-3.49)  0.109 
Current smoker, no. cases / controls 29 / 16 34 / 32 33 / 22 51 / 31 -  
Crude 1.0 0.60 (0.27-1.35) 0.85 (0.37-1.97) 0.92 (0.42-2.04)  0.701 
Adjusted for BMI 1.0 0.61 (0.27-1.36) 0.85 (0.37-1.97) 0.89 (0.40-1.97)  0.811 
 
13 
 
No. = number. Smaller number of subjects due to missing laboratory values of HbA1c. HbA1c category ranges (Q) in mmol/mol: Q1 = 28.9-35.5, Q2 = 36.6-38.8, Q3 = 39.9-
41.0, Q4 = 42.1-46.4, Q5 = 47.5-96.7. 
a.
 Category cut points of HbA1c were based on the distribution of controls. 
b.
 P trend test was based on median values of each category, adjusted for matching factors. 
c.
 Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last 
consumption of foods and drinks). Adjusting variables in further model: smoking (never smoker; former smoker who stopped < 10 years ago, ≥ 10 years ago; current 
smokers with 1-9, 10-19, or ≥ 20 cigarettes per day; smoking status unknown) and BMI (continuous). 
d.
 Self-reported diabetes at recruitment and/or HbA1c ≥ 6.5% (48 mmol/mol).  
e.
 Unconditional logistic regression, adjusted for matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling 
and last consumption of foods and drinks). Adjusting variables in subgroup analysis by median BMI: smoking (never smoker; former smoker who stopped < 10 years ago, 
≥ 10 years ago; current smokers with 1-9, 10-19, or ≥ 20 cigarettes per day; smoking status unknown). Adjusting variables in subgroup analysis by smoking status: BMI 
(continuous). 
Note: Uneven number of controls in Hb1c categories due to accuracy of laboratory HbA1c measurements. The laboratory assay measured HbA1c with 1 digit after the comma 
and this resulted in nodes of subjects with similar HbA1c values. Therefore, it is not possible to equally distribute HbA1c values of controls across the categories. The current 
distribution is based on a statistical method, which produces equal groups as accurately as possible.In subgroup analyses, HbA1c categories 4 and 5 were collapsed into one 
category. P interaction based on Wald test, crude p-interaction for median follow-up time = 0.320, median BMI = 0.627, smoking status = 0.604. 
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Table 3. Odds ratios (OR) for pancreatic cancer (95% CI) by categories of C-peptide overall, excluding diabetic subjects, and by fasting status 
 
 Categoriesa  
 1 2 3 4 Ρ trendb 
Quartile cut-offs [ng/ml] 0.08-2.95 2.99-5.46 5.48-9.26 9.27-19.82  
All subjects      
No. cases / controls 85 / 104 114 / 105 110 / 106 111 / 105  
Crudec 1.0 1.42 (0.93-2.16) 1.38 (0.89-2.13) 1.42 (0.90-2.23) 0.299 
Adjusted for smoking, BMI 1.0 1.27 (0.82-1.99) 1.16 (0.73-1.83) 1.15 (0.70-1.91) 0.886 
Excluding diabetic subjectsd      
No. cases / controls 78 / 85 95 / 85 86 / 91 86 / 84  
Crudec 1.0 1.25 (0.79-1.99) 1.06 (0.66-1.71) 1.15 (0.70-1.90) 0.851 
Adjusted for smoking, BMI 1.0 1.23 (0.76-1.99) 1.00 (0.61-1.65) 1.09 (0.64-1.87) 0.957 
By fasting statuse      
Non-fasting, no. cases / controls 18 / 24 41 / 38 46 / 51 65 / 60  
Crudec 1.0 1.44 (0.68-3.08) 1.21 (0.58-2.53) 1.44 (0.71-2.94) 0.503 
Adjusted for smoking, BMI 1.0 1.45 (0.67-3.13) 1.16 (0.54-2.47) 1.29 (0.62-2.70) 0.807 
In between, no. cases / controls 18 / 19 18 / 24 19 / 15 17 / 18  
Crudec 1.0 0.80 (0.32-1.96) 1.33 (0.52-3.39) 0.99 (0.39-2.54) 0.770 
Adjusted for smoking, BMI 1.0 0.65 (0.25-1.69) 0.85 (0.30-2.39) 0.60 (0.20-1.73) 0.472 
Fasting, no. cases / controls 44 / 51 40 / 34 24 / 21 9 / 5  
Crudec 1.0 1.39 (0.75-2.60) 1.38 (0.65-2.90) 2.20 (0.65-7.38) 0.186 
Adjusted for smoking, BMI 1.0 1.22 (0.61-2.45) 1.22 (0.53-2.83) 1.90 (0.44-8.11) 0.426 
No. = number, C-peptide concentrations on continuous scale were log transformed to achieve normality, smaller number of subjects due to missing laboratory values of C-
peptide. 
a.
 Category cut points were based on the distribution of controls. 
b.
 P trend test was based on median values of each category, adjusted for matching factors. 
c.
 Logistic regression conditioned on matching factors (EPIC recruitment centre, sex, age at recruitment, date at entry in the cohort, time between blood sampling and last 
consumption of foods and drinks). Adjusting variables in further models: smoking (former smokers adjusted for quitting smoking (< 10 or ≥ 10 years ago), current smokers 
adjusted for number of cigarettes (1-9, 10-19, or ≥ 20)), BMI (continuous). 
d.
 Self-reported diabetes at recruitment and/or HbA1c ≥ 6.5% (48 mmol/mol). 
e.
 Non-fasting = last intake < 3 hours ago, in between = last intake 3 - 6 hours ago, fasting = last intake ≥ 6 hours ago; p-interaction by fasting status based on Wald test: 
crude p = 0.905, BMI and smoking adjusted p = 0.806. 
 
